GlassScriptPhysician profile
Nik M Shah
NPI 1225022775
$3,925.73
in general payments reported to CMS, 2019-2025
44 companies · $738 in 2025
The $738 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,597 · 2020: $40.86 · 2021: $52.90 · 2023: $263 · 2024: $1,234 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,194 · Education: $41.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,193.90 |
| Education | $41.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $452.86 | 2019-2025 | |
| Pfizer INC. | $419.81 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $315.46 | 2019-2025 | Opdivo, Opdualag |
| Eisai INC. | $190.67 | 2019-2025 | |
| Celgene Corporation | $177.35 | 2024-2025 | Reblozyl, Recothrom, Opdivo |
| Merck Sharp & Dohme LLC | $176.34 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $173.59 | 2019-2024 | Xtandi |
| Sumitomo Pharma America, INC. | $161.61 | 2023-2024 | Orgovyx |
| Genentech USA, INC. | $152.44 | 2019-2024 | Venclexta |
| Astrazeneca Pharmaceuticals LP | $137.39 | 2019-2025 | Lynparza, Enhertu, Imfinzi |
| Daiichi Sankyo INC. | $123.65 | 2019-2025 | Enhertu |
| Incyte Corporation | $116.08 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Emd Serono, INC. | $110.39 | 2019-2024 | |
| Amgen INC. | $99.28 | 2019-2023 | Kyprolis |
| Gilead Sciences, INC. | $97.62 | 2019-2025 | Trodelvy |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nik Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.